GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab

 
• By Sue Sutter
  
Oncologic Drugs Advisry Committee Meeting has technical difficulties
FDA had to restart the ODAC meeting two hours after it originally began due to technical problems. • Source: Screen shot
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from United States

More from North America